Pharmacokinetics, safety and efficacy of saquinavir/ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy

Antiviral Therapy

Volumn 13, Issue 8, 2008, Pages 1039-1046

  von Hentig, Nils ^a   Nísius, Gabi ^a   Lennemann, Tessa ^a   Khaykin, Pavel ^a   Stephan, Christoph ^a   Babacan, Errol ^a   Staszewski, Schlomo ^a   Kurowski, Michael ^b   Harder, Sebastian ^a   Haberl, Annette ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Vivantes Auguste Viktoria Klinikum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTITIS; DEPRESSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBINURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KAPOSI SARCOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; NEPHROLITHIASIS; PANIC; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; THROMBOCYTOPENIA; VAGINITIS; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; AREA UNDER CURVE; FEMALE; HALF-LIFE; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; RITONAVIR; SAQUINAVIR;

EID: 58149510604     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Department for Health and Human Services (US). Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. (Updated 8 July 2008. Accessed 24 July 2008.) Available from http://www.aidsinfo.nih.gov/ ContentFiles/PerinatalGL.pdf
2. Department of Health and Human Services (US). Safety and toxicity of individual antiretroviral agents in pregnancy. (Updated 6 July 2006. Accessed September 2006.) Available from www.aidsinfo.nih.gov
3. Robert Koch Institut, Deutsche AIDS-Gesellschaft (DAIG), Österreichische AIDS-Gesellschaft (ÖAG). Deutsch-Österreichische Empfehlungen zur HIV-Therapie in der Schwangerschaft. 2003 (Updated 24 September 2008. Accessed 30 November 2008.) Available from www.rki.de/cln_091nn_753398/DE/Content/InFAZ/H/ HIVAIDS/Therapie/Leitlinien/PDF_D_A
4. Penzak SR, Acosta EP, Turner M, Tavel JA, Masur H. Analysis of generic nevirapine products in developing countries. JAMA 2003; 289:2648-2649.
5. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998; 178:368-374.
6. Mirochnick M, Siminski S, Fenton T, Lugo M, Sullivan JL. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J 2001; 20:803-805.
7. Phanuphak N, Apornpong T, Teeratakulpisarn S, et al. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med 2007; 8:357-366.
8. Jamisse I, Balkus J, Hitti J, et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr 2007; 44:371-376.
9. Marazzi MC, Germano P, Liotta G, et al. Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med 2006; 7:338-344.
10. Lyons F, Hopkins S, Kelleher B, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006; 7:255-260
11. McIntyre JA. Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV. Expert Opin Pharmacother 2006; 7:677-685.
12. von Hentig N, Carlebach A, Gute P, et al. A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol 2006; 62:552-559.
13. Vithayasai V, Moyle GJ, Supajatura V, et al. Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmission. J Acquir Immune Defic Syndr 2002; 30:410-412.
14. Acosta EP, Zorrilla C, Van Dyke R, et al. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials 2001; 2:460-465.
15. Acosta E, Bardeguez A, Zorrilla CD, et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chaemother 2004; 48:430-436.
16. Lopez-Cortes LF, Ruiz-Valderas R, Pascual R, Rodriguez M, Marin Niebla A. Once-daily saquinavir-hgc plus low-dose ritonavir (1200/100 mg) in HIV-infected pregnant women: pharmacokinetics and efficacy. HIV Clin Trials 2003; 4:227-229.
17. Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, et al. Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy. Ther Drug Monit 2007; 29:171-176.
18. Invirase (saquinavir mesylate). Invirase Product Information revised December 2003. Roche Laboratories Inc., Nutley, NJ, USA.
19. Invirase (saquinavir mesylate). Invirase Dear Doctor Letter issued May 2005. Roche Laboratories Inc., Nutley, NJ, USA.
20. Burger D, Eggink A, van der Ende M, et al. The pharmacokinetics of saquinavir new tablet formulation + ritonavir (1000/100 mg twice daily) in HIV-1 infected pregnant women. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 741.
21. Tung M, Boffito M, Taylor S, et al. Pharmacokinetics (PK), safety, tolerability and efficacy of boosted saquianvir 500 mg film coated tablets in a regimen of 1000/100 mg twice daily plus 2 nucleoside analogues (NRTIs) in HIV+ pregnant women. 8th International Congress on Drug Therapy in HIV Infection. 12-16 November 2006, Glasgow, UK. Abstract P383.
22. van der Lugt J. The influence of pregnancy on the pharmacokinetics of saquinavir boosted by low-dose ritonavir (1000/100 mg twice daily). 9th International Workshop on Clinical Pharmacology of HIV Therapy. 7-9 April 2008, New Orleans, LA, USA. Abstract 9.
23. Stephan C, von Hentig N, Kourbeti I, et al. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 2004; 18:503-508.
24. Maserati R, Villani P, Cocchi I, Regazzi M. Co-trimoxazole administered for Pneumocystis carinii pneumonia prophylaxis does not interfere with saquinavir pharmacokinetics. AIDS 1998; 12:815-816.
25. KKGT. International Interlaboratory Quality Control Program for therapeutic drug monitoring in HIV infection 2006. University of Nijmwege, the Netherlands. (Updated 30 September 2008. Accessed October 2008.) Available from http://kkgt.nl
26. Kurowski M, Sternfeld T, Sawyer A, Hill A, Mocklinghoff C. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med 2003; 4:94-100.
27. Boffito M, Kurowski M, Kruse G, et al. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir boosted once-daily regimen. AIDS 2004; 18:1291-1297.
28. Heinzel G (Editor). TOPFIT 2.0 Pharmacokinetic and pharmacodynamic data analysis system for the PC. Stuttgart: Gustav Fischer Verlag 1993.
29. AIDS Clinical Trials Group. Toxicity tables 2004. (Updated 9 August 2006. Accessed November 2008.) Available from http://rcc.tech-res.com/ tox_tables.htm
30. NIH. Common terminology criteria for adverse events (formerly CTC) V3.0. 2003 (Updated December 2004. Accessed November 2008.) Available from http://ctep.info.nih.gov/forms/CTCAEv3.pdf
31. Zorrilla CD, Van Dyke R, Bardeguez A, et al. Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants. Antimicrob Agents Chaemother 2007; 51:2208-2210.
32. Kosel BW, Beckerman K, Hayashi S, Homma M, Aweeka F. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 2003; 17:1195-1199.
33. Gingelmaier A, Kurowski M, Kastner R, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 2006; 20:1737-1743.
34. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004; 43:1071-1087.
35. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20:1931-1939.
36. Marzolini C, Kim RB. Placental transfer of antiretroviral drugs. Clin Pharmacol Ther 2005; 78:118-122.
37. Mirochnick M, Dorenbaum A, Holland D, et al. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J 2002; 21:835-838.
38. Gimenez F, Fernandez C, Mabondzo A. Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins. J Acquir Immune Defic Syndr 2004; 36:649-658.
39. Nettles RE, Kieffer TL, Parsons T, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006; 42:1189-1196.
40. von Hentig N, Babacan E, Staszewski S, Sturmer M, Doerr HW, Lotsch J. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients. Antivir Ther 2007; 12:1237-1246.